Home

John Duncan Higgons

CIK 1581954 · Chief Operating Officer · last filed 2022-06-28

John Duncan Higgons is a Chief Operating Officer who has filed 46 SEC Form 4 insider transactions across 2 companies since 2014. The most recent filing, for JNCE, was dated Jun 28, 2022. Across all open-market trades the lifetime net is −$21.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $4.3M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$4.35M

Companies

2

Total Filings

46

Lifetime Open-Market Net

-$21.37M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Jounce Therapeutics, Inc. (JNCE) Delisted Director 9,713 $1.88 $18.3K $67.9K 12 2022-06-28
AGIO Chief Operating Officer 120,834 $35.99 $4.35M -$21.43M 34 2016-01-05

Recent Filings

46 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-06-28 Jounce Therapeutics, Inc. (JNCE) Delisted Grant (A) — $0 EDGAR
2021-06-22 Jounce Therapeutics, Inc. (JNCE) Delisted Grant (A) — $0 EDGAR
2021-04-16 Jounce Therapeutics, Inc. (JNCE) Delisted Sell (S) −200 -$2.0K EDGAR
2021-03-17 Jounce Therapeutics, Inc. (JNCE) Delisted Sell (S) −200 -$2.6K EDGAR
2021-02-18 Jounce Therapeutics, Inc. (JNCE) Delisted Sell (S) −200 -$2.4K EDGAR
2021-01-22 Jounce Therapeutics, Inc. (JNCE) Delisted Sell (S) −1,700 -$20.2K EDGAR
2020-07-02 Jounce Therapeutics, Inc. (JNCE) Delisted Grant (A) — $0 EDGAR
2020-06-29 Jounce Therapeutics, Inc. (JNCE) Delisted Grant (A) — $0 EDGAR
2020-01-08 Jounce Therapeutics, Inc. (JNCE) Delisted Sell (S) −1,500 -$12.2K EDGAR
2019-06-13 Jounce Therapeutics, Inc. (JNCE) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 46
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.